Patents by Inventor Chong Ock Lee

Chong Ock Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240018123
    Abstract: The present disclosure provides a compound of a chemical structure having the ability of inhibiting or disintegrating an androgen receptor (AR), or a pharmaceutically acceptable salt of the compound. The present disclosure also provides a composition comprising such a compound or a pharmaceutically acceptable salt thereof. The present disclosure provides a pharmaceutical use of a compound according to the present disclosure, a salt thereof, and a composition comprising same for the treatment or prevention of AR-related diseases. The present disclosure also provides a method for treating or preventing AR-related diseases, comprising administering to a subject in need of treatment an effective amount of a compound according to the present disclosure, a salt thereof, or a composition comprising same.
    Type: Application
    Filed: July 28, 2021
    Publication date: January 18, 2024
    Inventors: Jong Yeon HWANG, Jae Du HA, Hyun Jin KIM, Sung Yun CHO, Pilho KIM, Chong Ock LEE, Jeong Hoon KIM, Byoung Chul PARK, Sung Goo PARK, Sunhong KIM, Yuri CHOI, Yaejin WOO, Song Hee LEE, Je Ho RYU, Jungmin AHN, Ji Youn PARK, Onnuri BAE, Hanwool KIM
  • Publication number: 20220009933
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating autoimmune diseases or tumors, containing, as an active ingredient, a tricyclic compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof, and a health food composition for preventing or alleviating autoimmune diseases or tumors, containing the tricyclic compound as an active ingredient, wherein the tricyclic compound represented by Chemical Formula 1 has an excellent inhibitory activity against IRAK4, and thus can be usefully used for the prevention, treatment, or alleviation of autoimmune diseases or tumors.
    Type: Application
    Filed: November 20, 2019
    Publication date: January 13, 2022
    Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Heeyeong Cho, Hee-Jong Lim, Woo Kyu Park, Dae Young Jeong, Hyeon Young Kim, Sae-Bom Yoon, Chong Ock Lee, Heung Kyoung Lee, Victor Sukbong HONG, Ji Hye Choi
  • Patent number: 11192878
    Abstract: The present disclosure relates to a novel piperidine-2,6-dione derivative and a use thereof and, more specifically, to a piperidine-2,6-dione derivative compound having a structure of a thalidomide analog. A compound of chemical formula 1 according to the present disclosure specifically binds with CRBN protein, and is involved in functions thereof. Therefore, the compound of the present disclosure can be favorably used in the prevention or treatment of leprosy, chronic graft versus host disease, an inflammatory disease, or cancer, which are caused by actions of CRBN protein.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: December 7, 2021
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Jong Yeon Hwang, Jae Du Ha, Sung Yun Cho, Pil Ho Kim, Chang Soo Yun, Chi Hoon Park, Chong Ock Lee, Sang Un Choi, Joo Youn Lee, Sunjoo Ahn
  • Patent number: 11084824
    Abstract: The present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and brain disease. The pyrazolopyrimidine derivative of the present invention exhibits excellent Bruton's tyrosine kinase inhibition activity, so that it can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: August 10, 2021
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Pilho Kim, Sung Yun Cho, Jae Du Ha, Hyoung Rae Kim, Jong Yeon Hwang, Chang Soo Yun, Hee Jung Jung, Chi Hoon Park, Chong Ock Lee, Chang Hoon Lee, Sunjoo Ahn
  • Publication number: 20200199129
    Abstract: The present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and brain disease. The pyrazolopyrimidine derivative of the present invention exhibits excellent Bruton's tyrosine kinase inhibition activity, so that it can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.
    Type: Application
    Filed: May 14, 2018
    Publication date: June 25, 2020
    Inventors: Pilho Kim, Sung Yun Cho, Jae Du Ha, Hyoung Rae Kim, Jong Yeon Hwang, Chang Soo Yun, Hee Jung Jung, Chi Hoon Park, Chong Ock Lee, Chang Hoon Lee, Sunjoo Ahn
  • Publication number: 20200062730
    Abstract: The present disclosure relates to a novel piperidine-2,6-dione derivative and a use thereof and, more specifically, to a piperidine-2,6-dione derivative compound having a structure of a thalidomide analog. A compound of chemical formula 1 according to the present disclosure specifically binds with CRBN protein, and is involved in functions thereof. Therefore, the compound of the present disclosure can be favorably used in the prevention or treatment of leprosy, chronic graft versus host disease, an inflammatory disease, or cancer, which are caused by actions of CRBN protein.
    Type: Application
    Filed: May 11, 2018
    Publication date: February 27, 2020
    Inventors: Jong Yeon HWANG, Jae Du HA, Sung Yun CHO, Pil Ho KIM, Chang Soo YUN, Chi Hoon PARK, Chong Ock LEE, Sang Un CHOI, Joo Youn LEE, Sunjoo AHN
  • Patent number: 10369149
    Abstract: The present invention relates to a 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: August 6, 2019
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Jong Yeon Hwang, Hyoung Rae Kim, Jae Du Ha, Sung Yun Cho, Hee Jung Jung, Pilho Kim, Chang Soo Yun, Chong Ock Lee, Chi Hoon Park, Chong Hak Chae, Sunjoo Ahn
  • Patent number: 10100019
    Abstract: The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: October 16, 2018
    Assignee: Korea Research Institute of Chemical Technology
    Inventors: Pilho Kim, Hyoung Rae Kim, Sung Yun Cho, Jae Du Ha, Hee Jung Jung, Chang Soo Yun, Jong Yeon Hwang, Chi Hoon Park, Chong Ock Lee, Sunjoo Ahn, Chong Hak Chae
  • Patent number: 10053458
    Abstract: The present invention relates to a pyrimidine-2,4-diamine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the same as an effective ingredient. A compound according to the present invention has the good effect of inhibiting anaplastic lymphoma kinase (ALK) activity, whereby a therapeutic effect on cancer cells having an anaplastic lymphoma kinase (ALK) fusion protein such as EML4-ALK, NPM-ALK, etc. can be enhanced and it is expected that a recurrence of cancer will be effectively inhibited. As such, the compound can be effectively used in a pharmaceutical composition for prevention or treatment of cancer.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: August 21, 2018
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Chang Soo Yun, Hyoung Rae Kim, Sung Yun Cho, Hee Jung Jung, Kwangho Lee, Chong Hak Chae, Chong Ock Lee, Chi Hoon Park, Pilho Kim, Jong Yeon Hwang, Jae Du Ha, Sun Joo Ahn
  • Publication number: 20180111905
    Abstract: The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
    Type: Application
    Filed: April 6, 2016
    Publication date: April 26, 2018
    Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Pilho Kim, Hyoung Rae Kim, Sung Yun Cho, Jae Du Ha, Hee Jung Jung, Chang Soo Yun, Jong Yeon Hwang, Chi Hoon Park, Chong Ock Lee, Sunjoo Ahn, Chong Hak Chae
  • Publication number: 20180104242
    Abstract: The present invention relates to a 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
    Type: Application
    Filed: December 30, 2015
    Publication date: April 19, 2018
    Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Jong Yeon HWANG, Hyoung Rae KIM, Jae Du HA, Sung Yun CHO, Hee Jung JUNG, Pilho KIM, Chang Soo YUN, Chong Ock LEE, Chi Hoon PARK, Chong Hak CHAE, Sunjoo AHN
  • Publication number: 20170145007
    Abstract: The present invention relates to a pyrimidine-2,4-diamine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the same as an effective ingredient. A compound according to the present invention has the good effect of inhibiting anaplastic lymphoma kinase (ALK) activity, whereby a therapeutic effect on cancer cells having an anaplastic lymphoma kinase (ALK) fusion protein such as EML4-ALK, NPM-ALK, etc. can be enhanced and it is expected that a recurrence of cancer will be effectively inhibited. As such, the compound can be effectively used in a pharmaceutical composition for prevention or treatment of cancer.
    Type: Application
    Filed: May 21, 2015
    Publication date: May 25, 2017
    Inventors: Chang Soo YUN, Hyoung Rae KIM, Sung Yun CHO, Hee Jung JUNG, Kwangho LEE, Chong Hak CHAE, Chong Ock LEE, Chi Hoon PARK, Pilho KIM, Jong Yeon HWANG, Jae DU HA, Sun Joo AHN
  • Patent number: 9403831
    Abstract: The present invention relates to a novel triazolopyrazine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating hyper proliferative disorder. The present invention can be useful as a therapeutic agent for various hyper proliferative disorders associated with excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy, by efficiently inhibiting c-Met tyrosine kinase activity.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: August 2, 2016
    Assignees: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, HANDOK INC.
    Inventors: Hee Jung Jung, Jae Du Ha, Sung Yun Cho, Hyoung Rae Kim, Kwang Ho Lee, Chong Ock Lee, Sang Un Choi, Chi Hoon Park
  • Patent number: 9199944
    Abstract: Disclosed herein are a new N2,N4-bis(4-(piperazin-1-yl)phenyl)pyrimidin-2,4-diamine derivative or a pharmaceutically acceptable salt thereof and a pharmaceutical composition for the prevention or treatment of cancers containing the same as an active ingredient. The compound of the present invention has excellent inhibitory effects against the activities of anaplastic lymphoma kinase (ALK) and activated cdc42-associated kinase (ACK1) and thus can improve the therapeutic effects on the treatment of cancer cells having anaplastic lymphoma kinase fusion proteins such as EML4-ALK and NPM-ALK, and also effectively prevent the recurrence of cancers thus being useful as a pharmaceutical composition for the prevention and treatment of cancers.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: December 1, 2015
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Kwangho Lee, Hyoung Rae Kim, Chi Hoon Park, Chong Ock Lee, Jong Kook Lee, Hee Jung Jung, Sung Yun Cho, Chong Hak Chae, Sang Un Choi, Jae Du Ha
  • Publication number: 20150259350
    Abstract: The present invention relates to a novel triazolopyrazine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating hyper proliferative disorder. The present invention can be useful as a therapeutic agent for various hyper proliferative disorders associated with excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy, by efficiently inhibiting c-Met tyrosine kinase activity.
    Type: Application
    Filed: September 30, 2013
    Publication date: September 17, 2015
    Inventors: Hee Jung Jung, Jae Du Ha, Sung Yun Cho, Hyoung Rae Kim, Kwang Ho Lee, Chong Ock Lee, Sang Un Choi, Chi Hoon Park
  • Publication number: 20150152069
    Abstract: Disclosed herein are a new N2,N4-bis(4-(piperazin-1-yl)phenyl)pyrimidin-2,4-diamine derivative or a pharmaceutically acceptable salt thereof and a pharmaceutical composition for the prevention or treatment of cancers containing the same as an active ingredient. The compound of the present invention has excellent inhibitory effects against the activities of anaplastic lymphoma kinase (ALK) and activated cdc42-associated kinase (ACK1) and thus can improve the therapeutic effects on the treatment of cancer cells having anaplastic lymphoma kinase fusion proteins such as EML4-ALK and NPM-ALK, and also effectively prevent the recurrence of cancers thus being useful as a pharmaceutical composition for the prevention and treatment of cancers.
    Type: Application
    Filed: February 9, 2015
    Publication date: June 4, 2015
    Inventors: Kwangho LEE, Hyoung Rae KIM, Chi Hoon PARK, Chong Ock LEE, Jong Kook LEE, Hee Jung JUNG, Sung Yun CHO, Chong Hak CHAE, Sang Un CHOI, Jae Du HA
  • Patent number: 7279497
    Abstract: The present invention relates to benzopyran derivatives substituted with secondary amines including imidazole, their preparation, and pharmaceutical compositions containing them. The present invention is pharmacologically useful for the treatment of cancer, rheumatoid arthritis, and diabetic retinopathies through anti-angiogenic properties, and also pharmacologically useful in the protection of heart and neuronal cells against ischemia-reperfusion injury or preserving organs.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: October 9, 2007
    Assignee: Korea Research Institute of Chemical Technology
    Inventors: Kyu Yang Yi, Sun Kyung Lee, Sung-Eun Yoo, Jee Hee Suh, Nak Jeong Kim, Sun Kyung Hwang, Byung-Ho Lee, Ho Won Seo, Chong Ock Lee, Sang-Un Choi
  • Patent number: 7160884
    Abstract: The present invention relates to 1-/2-substituted-1H/-2H-[1,2,3]triazolo[4,5-g]phthalazine-4,9-dione compounds and their pharmaceutically acceptable salts, a process for preparing the compounds and a pharmaceutical composition comprising the compounds. The compounds are shown to effectively inhibit cell proliferation and are thus expected to be used for treatment or prevention or treatment of various cancers or as an ancillary(auxiliary) means of the same.
    Type: Grant
    Filed: January 12, 2006
    Date of Patent: January 9, 2007
    Assignee: EWHA University-Industry Collaboration Foundation
    Inventors: Hea Young Park Choo, Jin Sung Kim, Hee Kyung Rhee, Hyun Joo Park, Sang Kook Lee, Chong Ock Lee
  • Publication number: 20040043083
    Abstract: A pharmaceutical composition comprising a lower alcohol-soluble extract of Ferula asafoedida L or a compound isolated therefrom including galbanic acid, karatavicinol, umbelliprenin, farnesiferol B, or farnesiferol C exhibits a potent anticancer activity.
    Type: Application
    Filed: April 10, 2003
    Publication date: March 4, 2004
    Inventors: Shi-Yong Ryu, Chong-Ock Lee, Sang-Un Choi, Sung-Hee Park, Young-Sup Kim, Sung-Ki Kim, Sang-Keun Kim, Shin-Kwon Kang
  • Patent number: 6221906
    Abstract: The present invention relates to a platinum complex conjugated to a cyclotriphosphazene represented by Formula 1 and a preparation method thereof. The platinum complex according to the present invention can be used as an anticancer agent.
    Type: Grant
    Filed: March 2, 2000
    Date of Patent: April 24, 2001
    Assignee: Korea Institute of Science and Technology
    Inventors: Youn Soo Sohn, Hyoung Gee Baek, Chong Ock Lee